Core Insights - The article highlights the emergence of Danno Pharmaceuticals as a key player in the biotechnology sector, focusing on innovative drug products targeting bacterial infections and related diseases, particularly with its lead product, Rifoternizole, which aims to be the first new molecular entity for Helicobacter pylori infection since its discovery [1][7]. Group 1: Technology Platform and Product Pipeline - Danno Pharmaceuticals has established a dual barrier through its proprietary multi-target conjugate molecule technology, which is pivotal for drug development in bacterial infections and related diseases [2]. - The company boasts a globally leading multi-target conjugate molecule technology platform that integrates the entire drug design, synthesis, and evaluation process, significantly reducing development risks associated with safety and efficacy [3]. - As of January 24, 2026, Danno holds 42 authorized patents and 87 patent applications, providing robust intellectual property protection for its core products [3]. Group 2: Differentiated Product Pipeline - Danno's product pipeline consists of seven innovative assets targeting major unmet clinical needs, including Helicobacter pylori infection and other bacterial-related conditions, with all products intended as first-line or initial treatment options [4]. - The pipeline includes one product nearing commercialization (Rifoternizole), two in late-stage clinical development (Rifoketone injection and TNP-2092 oral formulation), one with IND approval, and three in preclinical stages [4]. Group 3: Global Development Strategy - Danno Pharmaceuticals has initiated or is conducting a total of 16 clinical trials in China and the U.S. for its pipeline products, with core products positioned for global development [6]. - Rifoternizole and Rifoketone have received multiple FDA designations, including QIDP, orphan drug, and fast track status, laying the groundwork for international commercial expansion [6]. Group 4: Core Product - Rifoternizole - Rifoternizole (TNP-2198) is the first new molecular entity for treating Helicobacter pylori infection since 1982, showcasing a unique multi-target synergistic mechanism that effectively targets both microaerophilic and anaerobic bacteria [7]. - Clinical trials in China demonstrated that Rifoternizole's three-drug regimen achieved non-inferiority compared to the bismuth quadruple therapy, with a success rate of 92.0% versus 87.9% [7]. - The early clinical results of Rifoternizole have been published in The Lancet Infectious Diseases, and the product has garnered significant media attention, reflecting its clinical value and societal significance [8]. Group 5: Commercialization Pathway - Danno Pharmaceuticals submitted a new drug application for Rifoternizole to the National Medical Products Administration in August 2025, with expectations for approval by the end of 2026 [12]. - The company has signed an exclusive commercialization agreement with Yuan Da Life Sciences for Rifoternizole in Greater China, ensuring rapid market penetration post-approval [12]. - The market potential for Rifoternizole is substantial, with an estimated 621.1 million people infected with Helicobacter pylori in China and 4.081 billion globally, highlighting the significant unmet medical need [12]. Group 6: Other Key Products - Rifoketone (TNP-2092 injection) is positioned as the first clinical candidate effective against biofilm infections, with a multi-target mechanism that enhances its efficacy against traditional antibiotic resistance [13]. - TNP-2092 oral formulation shows promise in treating metabolic-related diseases, with a low spontaneous resistance rate and superior activity against gut bacteria compared to existing treatments [14]. - The global market for artificial joint infections is projected to grow significantly, indicating a vast potential for Danno's products in addressing these critical health issues [14].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 TenNor Therapeutics (Suzhou) Limited 丹諾醫藥（蘇州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處長登記 前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請， 有意投資者務請僅依據送呈香港公司註冊處處長登記的本公司招股章程作出投資決定；有關文本將 於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本 文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其保薦人、整體協 調人、顧問或包銷團成員在香港或任何其他司法權區必須進行發售活動的責任。本公司最終 會否進行發售仍屬未知之數； (c) 本文件或其任何補充、修訂或更換附頁的內 ...

Core Viewpoint - Danuo Pharmaceutical, a biotech company based in Suzhou, is on the verge of submitting a new drug application for the world's first and only new molecular entity candidate for treating Helicobacter pylori infection, marking a significant milestone in the field of antibiotic development [5][10][14]. Company Overview - Founded in 2013 by Ma Zhenkun, Danuo Pharmaceutical focuses on developing treatments for bacterial infections and related diseases, with a strong emphasis on Helicobacter pylori [8][9]. - The company has a pipeline of seven drugs in development, including "Rifotnizole," which has successfully completed Phase III clinical trials [10][13]. Investment and Financials - Danuo Pharmaceutical has successfully raised funds through multiple financing rounds, reaching a valuation of over 2 billion yuan after its E round [15][17]. - The company has accumulated a net loss of 192 million yuan in 2023, which decreased to 146 million yuan in 2024, indicating a positive trend in financial performance [14]. Market Potential - The global market for antibacterial drugs is projected to grow from $45.5 billion in 2024 to $60.3 billion by 2029, with the market for Helicobacter pylori treatments expected to increase from $6.9 billion to $10 billion in the same period [14]. Strategic Partnerships - Danuo has established a commercial partnership with Yuan Da Life Science Group for the marketing and distribution of "Rifotnizole," which includes a payment agreement potentially worth up to 775 million yuan [14][17]. Future Outlook - The company plans to submit the new drug application for "Rifotnizole" by the end of August 2025 and aims to establish a drug production and R&D base in Zhongshan, Guangdong [17][18].